New-onset and flares of psoriasis after COVID-19 infection or vaccination successfully treated with biologics: a case series

Figures & data

Table 1. Demographic and clinical characteristics of our 28 patients.

Age	Gender	Type of psoriasis	Onset	Duration of psoriasis (years)	Trigger	Type of vaccine	Dose of vaccine	Biologic	PASI baseline	PASI Week 16
38	F	Guttate	Severe Exacerbation	18	COVID Infection	NA	NA	Risankizumab	22	0
28	M	Guttate	Severe Exacerbation	10	COVID Infection	NA	NA	Risankizumab	18	0
42	M	Plaque	De Novo	2	COVID Infection	NA	NA	Risankizumab	14.7	0
40	F	Plaque	Severe Exacerbation	19	COVID Vaccine	BNT162b2	III	Tildrakizumab	10	0
50	M	Plaque	Severe Exacerbation	4	COVID Vaccine	BNT162b2	II	Tildrakizumab	10	3
25	M	Plaque	Severe Exacerbation	2	COVID Vaccine	BNT162b2	II	Ixekizumab	30	0
82	F	Plaque	De Novo	1	COVID Vaccine	BNT162b2	III	Secukinumab	14	0.6
40	F	Plaque	Severe Exacerbation	28	COVID Vaccine	mRNA-1273	III	Tildrakizumab	10	1
53	M	Plaque	Severe Exacerbation	21	COVID Vaccine	BNT162b2	II	Risankizumab	30	0
50	M	Plaque	Severe Exacerbation	32	COVID Vaccine	BNT162b2	II	Guselkumab	9.5	0
29	M	Pustular	De Novo	1	COVID Vaccine	BNT162b2	II	Guselkumab	2	0
38	M	Plaque	Severe Exacerbation	17	COVID Vaccine	BNT162b2	II	Risankizumab	10	0
62	F	Plaque	Severe Exacerbation	32	COVID Infection	NA	NA	Risankizumab	6	2
56	M	Plaque	Severe Exacerbation	8	COVID Vaccine	BNT162b2	I	Secukinumab	12	0
50	M	Plaque	Severe Exacerbation	32	COVID Vaccine	mRNA-1273	II	Brodalumab	30	0
78	M	Plaque	Severe Exacerbation	54	COVID Vaccine	BNT162b2	III	Risankizumab	24	1
67	F	Plaque	Severe Exacerbation	52	COVID Vaccine	BNT162b2	III	Risankizumab	21.6	0
59	M	Plaque	Severe Exacerbation	39	COVID Infection	NA	NA	Risankizumab	18	3
57	M	Guttate	Severe Exacerbation	20	COVID Vaccine	BNT162b2	II	Guselkumab	6	0
53	M	Plaque	Severe Exacerbation	8	COVID Vaccine	BNT162b2	II	Bimekizumab	8	1
61	M	Plaque	Severe Exacerbation	26	COVID Vaccine	mRNA-1273	II	Risankizumab	12	5
47	M	Guttate	Severe Exacerbation	4	COVID Infection	NA	NA	Risankizumab	10.5	1.5
84	F	Plaque	Severe Exacerbation	62	COVID Infection	NA	NA	ustekinumab	6	0
61	M	Plaque	Severe Exacerbation	8	COVID Infection	NA	NA	Risankizumab	12	0.4
72	F	Plaque	Severe Exacerbation	22	COVID Vaccine	BNT162b2	II	Ustekinumab	2	0
43	M	Plaque	Severe Exacerbation	25	COVID Infection	NA	NA	Secukinumab	20	2
76	M	Plaque	Severe Exacerbation	42	COVID Vaccine	BNT162b2	III	Guselkumab	10	0
34	F	Plaque	Severe Exacerbation	15	COVID Infection	NA	NA	Tildrakizumab	4	1

Abbreviations: PASI: psoriasis area and severity index; NA: not applicable.